Ignite Creation Date:
2024-05-05 @ 4:46 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00310687
Status:
COMPLETED
Last Update Posted:
2014-09-19
First Post:
2006-04-03
Brief Title:
Persistence of Immune Response After Vaccination With MCC
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A Phase IV Single Centre Open-label Study to Evaluate the Persistence of Antibodies in Adolescents 14-16 Years of Age Vaccinated With Chiron Meningococcal C Conjugate Vaccine During the 1999-2001 UK MenCC Immunization Campaign at One Year After Either a Challenge Dose of Aventis Pasteur MSD Meningococcal AC Polysaccharide Vaccine or a Booster Dose of MenC Vaccine in Parallel to Subjects Aged 11-20 Evaluated at 4 Years After Vaccination During the 1999-2001 UK MenCC Immunization Campaign
Status:
COMPLETED
Status Verified Date:
2014-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Persistence of Immune response after vaccination with MCC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| Impact N 919 | None | None | None |